Blog
RSS FeedPosted by Michael Wonder on 01 Jun 2023
Antengene announces Xpovio plus bortezomib and dexamethasone included for reimbursement by the PBS in Australia for the treatment of relapsed and/or refractory multiple myeloma
31 May 2023 - This inclusion by the PBS for the treatment of patients with relapsed and/or refractory multiple myeloma who ...
Posted by Michael Wonder on 25 May 2023
Australians battling with prostate cancer to benefit from new PBS listing
25 May 2023 - Australians battling prostate cancer that has spread past the prostate will soon benefit from subsidised medicine ...
Posted by Michael Wonder on 21 May 2023
Is the quality of evidence in health technology assessment deteriorating over time? A case study on cancer drugs in Australia.
18 May 2023 - This study aimed to assess whether there have been changes in the quality of clinical evidence ...
Posted by Michael Wonder on 16 Apr 2023
Price of a life: Australians wait two years longer for breakthrough medicines than US citizens
16 April 2023 - Australians are waiting two years longer to access new lifesaving subsidised medicines because of pharma giants. Now, ...
Posted by Michael Wonder on 16 Apr 2023
Australian cancer patients spend $200 million a year on treatments not on the PBS and it’s got to change
16 April 2023 - Australian cancer patients were spending in excess of $200m each year of their own money on therapies ...
Posted by Michael Wonder on 31 Jan 2023
Call for Enhertu to be registered on Pharmaceutical Benefits Scheme
31 January 2023 - Sarah Lee has been forced to use her super and life insurance to pay for the treatment. ...
Posted by Michael Wonder on 03 Dec 2022
Hopes $55k breast cancer drug Keytruda will get PBS listing
3 December 2022 - Women with triple negative breast cancer have been given new hope that immunotherapy drug Keytruda will ...
Posted by Michael Wonder on 01 Nov 2022
First immunotherapy for patients with a potentially life threatening type of non-melanoma skin cancer now available on the PBS
1 November 2022 - Australians with a potentially life-threatening type of non-melanoma skin cancer will for the first time, have ...
Posted by Michael Wonder on 10 Oct 2022
Ground breaking platform launched for Aboriginal and Torres Strait Islander people affected by cancer
10 October 2022 - Australia’s first comprehensive cancer website developed by and for Indigenous Australians has officially launched today in a ...
Posted by Michael Wonder on 04 Oct 2022
Landmark PBS listing for treatment of gastro-oesophageal cancers
1 October 2022 - From 1 October, Australians with advanced or metastatic gastro-oesophageal cancers will have access to new treatment through ...
Posted by Michael Wonder on 26 Sep 2022
Patients will pay less for critical medicines including ‘miracle’ cancer drug
26 September 2022 - Australians will have cheaper access to medicines for migraines, arthritis, bipolar, stomach ulcers and several cancers. ...
Posted by Michael Wonder on 10 Sep 2022
Your money or your life? Cancer’s crushing cost
10 September 2022 - The first thing many cancer patients see when they arrive at the oncology ward is the EFTPOS ...
Posted by Michael Wonder on 09 Sep 2022
Rare cancer sufferers fight to get drugs on PBS
9 September 2022 - People with rare cancers are being forced to sell their homes, raid their superannuation and fundraise ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 01 Sep 2022
Antengene announces Xpovia included for reimbursement by the PBS in Australia for the treatment of patients with relapsed and/or refractory multiple myeloma
1 September 2022 - Xpovio (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the ...